# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Dwight D. Eisenhower (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET015-SYN-TD
- Date: 1956-03-16
- Fictional facility: St. Posthumous Health Center
- Fictional author: Russell Okonkwo, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Lipid review nine weeks after adding ezetimibe. **S**

## History of present illness

Mr. Eisenhower returns for his lipid review. He has been back at full-time work for seven weeks, including two trips by air, without chest pain, breathlessness, or undue fatigue. He walks 40 minutes on most days and has started hitting golf balls at the practice range. He has had no muscle aches on atorvastatin and ezetimibe, and his home blood pressure averages 122/76. **S**

| Element | Detail |
|---|---|
| Interval change | Full-time work for seven weeks; air travel tolerated |
| Exercise | Walking most days; golf practice resumed |
| Medication tolerance | No myalgia on atorvastatin and ezetimibe |
| Home blood pressure | Average 122/76 |
| Nitroglycerin use | None |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fatigue or weight gain |
| Cardiovascular | Negative | No chest pain, palpitations, or edema |
| Respiratory | Negative | No breathlessness on stairs or walking |
| Musculoskeletal | Negative | No muscle aches or weakness |
| Psychiatric | Negative | Mood good; sleeping well; PHQ-2 score 0 |

5 systems reviewed. **S**

## Current medications

- Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily **S**
- Ticagrelor 90 mg oral tablet, one tablet by mouth twice daily **S**
- Atorvastatin 80 mg oral tablet, one tablet by mouth daily **S**
- Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily **S**
- Lisinopril 10 mg oral tablet, one tablet by mouth daily **S**
- Ezetimibe 10 mg oral tablet, one tablet by mouth daily **S**
- Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue every 5 minutes as needed for chest pain, up to 3 tablets; call 911 if pain is not better 5 minutes after the first tablet **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/76 mmHg; pulse 58 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 78 kg; BMI 24.6 kg/m². All vital signs are synthetic.

Total cholesterol: 118 mg/dL; HDL cholesterol: 44 mg/dL; Triglycerides: 120 mg/dL; LDL cholesterol: 50 mg/dL; ALT: 26 U/L; PHQ-2: 0. All results are synthetic.

## Change since baseline

- Total cholesterol: 150 mg/dL at baseline, 118 mg/dL at this visit **S**
- HDL cholesterol: 42 mg/dL at baseline, 44 mg/dL at this visit **S**
- Triglycerides: 150 mg/dL (high) at baseline, 120 mg/dL at this visit **S**
- LDL cholesterol: 78 mg/dL at baseline, 50 mg/dL at this visit **S**
- ALT: 24 U/L at baseline, 26 U/L at this visit **S**
- PHQ-2: 1 at baseline, 0 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well and energetic |
| Heart | Regular rhythm; no murmur or gallop |
| Lungs | Clear |
| Extremities | No edema |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Hyperlipidemia** (E78.5). LDL cholesterol has fallen from 78 to 50 mg/dL on atorvastatin 80 mg and ezetimibe 10 mg, below the goal of 55 mg/dL. ALT normal. **S**
   - Continue atorvastatin 80 mg and ezetimibe 10 mg.
   - Lipid panel at the one-year review.
2. **Coronary artery disease after stenting** (I25.10). No angina at full-time work. **S**
   - Continue aspirin and ticagrelor to twelve months, metoprolol, and lisinopril.
3. **Essential hypertension** (I10). Blood pressure 124/76 mmHg, at goal. **S**
   - No change.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Lipid panel | 4 to 12 weeks after starting or changing therapy, then every 3 to 12 months | Completed today | Nine weeks after adding ezetimibe, within the 4-to-12-week window of the ischemic heart disease and hyperlipidemia monographs and one week past the AMI monograph's 4-to-8-week window. LDL cholesterol 50 mg/dL, at goal |
| Laboratory | ALT | Baseline, then only with symptoms | Completed today | 26 U/L, normal; checked with the lipid panel because ezetimibe was added |
| Laboratory | Basic metabolic panel | 1 to 2 weeks after starting or changing an ACE inhibitor, then every 6 months | Up to date | Normal two weeks after the lisinopril increase; next due in about four months |
| Examination | Blood pressure, heart rate, weight and BMI, heart and lungs, edema | Every visit | Completed today | Blood pressure 124/76 mmHg, weight 78.0 kg |
| Medication safety | Antiplatelet, statin, beta-blocker, and ACE inhibitor adherence and tolerance | Every visit | Completed today | Taking all doses; no bleeding beyond bruising; no myalgia |
| Survey | Depression screen (PHQ-2) | Every visit | Completed today | Score 0 |
| Self-management | Tobacco use | Every visit | Completed today | Abstinent |
| Self-management | Physical activity and diet | Every visit | Completed today | At least 150 minutes a week of moderate activity |
| Imaging | Stress testing or repeat echocardiography | Only with new or changing symptoms | Not indicated | No symptoms; routine surveillance testing is not recommended |

## Goal progress

- Lower LDL cholesterol below 55 mg/dL by the lipid recheck in about two months. Outcome by 1956-03-16: LDL cholesterol 50 mg/dL on atorvastatin and ezetimibe. **S**
- Keep blood pressure below 130/80 mmHg. Outcome by 1956-03-16: Blood pressure 124/76 mmHg on lisinopril 10 mg and metoprolol. **S**
- Return to full-time work and travel by the seven-month review. In progress; target 1956-05-11. **S**
- Keep at least 150 minutes a week of moderate exercise after cardiac rehabilitation. In progress; target 1956-05-11. **S**
- Complete twelve months of dual antiplatelet therapy without major bleeding. In progress; target 1956-09-28. **S**

## Guideline basis

- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023), American Heart Association and American College of Cardiology
- CMID: Clinical Monitoring Intelligence Database, acute myocardial infarction, ischemic heart disease, hyperlipidemia, and hypertension monographs (2026), Aether Forge

## Follow-up

- Coronary disease review in about two months. **S**
- Next scheduled visit 1956-05-11: seven-month coronary disease review after return to full-time work. **S**
